1. Home
  2. ZTR vs ALT Comparison

ZTR vs ALT Comparison

Compare ZTR & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZTR
  • ALT
  • Stock Information
  • Founded
  • ZTR 1988
  • ALT 1997
  • Country
  • ZTR Australia
  • ALT United States
  • Employees
  • ZTR N/A
  • ALT N/A
  • Industry
  • ZTR Investment Managers
  • ALT Biotechnology: Pharmaceutical Preparations
  • Sector
  • ZTR Finance
  • ALT Health Care
  • Exchange
  • ZTR Nasdaq
  • ALT Nasdaq
  • Market Cap
  • ZTR 349.4M
  • ALT 292.0M
  • IPO Year
  • ZTR N/A
  • ALT N/A
  • Fundamental
  • Price
  • ZTR $6.37
  • ALT $3.83
  • Analyst Decision
  • ZTR
  • ALT Strong Buy
  • Analyst Count
  • ZTR 0
  • ALT 6
  • Target Price
  • ZTR N/A
  • ALT $17.40
  • AVG Volume (30 Days)
  • ZTR 219.4K
  • ALT 3.0M
  • Earning Date
  • ZTR 01-01-0001
  • ALT 08-12-2025
  • Dividend Yield
  • ZTR 12.09%
  • ALT N/A
  • EPS Growth
  • ZTR N/A
  • ALT N/A
  • EPS
  • ZTR N/A
  • ALT N/A
  • Revenue
  • ZTR N/A
  • ALT $20,000.00
  • Revenue This Year
  • ZTR N/A
  • ALT N/A
  • Revenue Next Year
  • ZTR N/A
  • ALT $761,880.20
  • P/E Ratio
  • ZTR N/A
  • ALT N/A
  • Revenue Growth
  • ZTR N/A
  • ALT N/A
  • 52 Week Low
  • ZTR $4.50
  • ALT $2.90
  • 52 Week High
  • ZTR $6.60
  • ALT $11.16
  • Technical
  • Relative Strength Index (RSI)
  • ZTR 64.07
  • ALT 51.79
  • Support Level
  • ZTR $6.27
  • ALT $3.35
  • Resistance Level
  • ZTR $6.35
  • ALT $3.66
  • Average True Range (ATR)
  • ZTR 0.04
  • ALT 0.19
  • MACD
  • ZTR 0.01
  • ALT 0.07
  • Stochastic Oscillator
  • ZTR 85.06
  • ALT 86.18

About ZTR Virtus Total Return Fund Inc.

Virtus Total Return Fund Inc is a closed-end, diversified management investment company. Its investment objective of capital appreciation, with current income as a secondary objective. The Fund seeks to meet its objectives through a balance of equity and fixed income investments.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: